Overview

The only GHRH-class peptide with full FDA approval. It raises endogenous growth hormone in a pulsatile, physiological pattern rather than replacing it, and has real trial data for visceral fat reduction.

FDA ApprovedFDA-approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy

At a glance

Regulatory status	FDA-approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy
Drug class	Stabilised growth hormone-releasing hormone (GHRH) analog
Route	Subcutaneous, once daily
Half-life	~26–38 minutes
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong Multiple phase 3 randomized trials plus regulatory approval in a major market.
Studied in	Two phase 3 trials in HIV-associated lipodystrophy; investigator-led studies in NAFLD and in HIV-associated cognitive complaints.

How it works

Binds pituitary GHRH receptors to stimulate endogenous GH secretion, preserving negative feedback and pulsatility. The resulting GH/IGF-1 rise promotes lipolysis, with a disproportionate effect on visceral adipose tissue.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

Two adequately powered phase 3 trials with imaging endpoints.
Positive independent NIH-funded trial in a second indication.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Selective visceral fat reduction Strong evidence

Roughly 15–18% reduction in visceral adipose tissue by CT over 26 weeks, without equivalent loss of subcutaneous fat.
Triglyceride improvement Moderate evidence

Consistent reductions in triglycerides accompanied the visceral fat loss.
Liver fat reduction Moderate evidence

An NIH-supported randomized trial showed reduced hepatic fat and slowed fibrosis progression in people with HIV and NAFLD.
Physiological GH pattern Moderate evidence

Preserves pituitary feedback, so it does not suppress the axis the way exogenous GH does.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Glucose intolerance Moderate evidence

GH is counter-regulatory to insulin; fasting glucose and HbA1c can rise, occasionally unmasking diabetes.
Fluid retention, arthralgia, carpal tunnel Moderate evidence

Classic GH-excess side effects, dose-related.
Contraindicated in active malignancy Serious

GH/IGF-1 elevation is avoided where a growth-sensitive tumour may be present.
Benefit reverses on stopping Moderate evidence

Visceral fat returns after discontinuation; it is chronic therapy.
Injection-site reactions and hypersensitivity Minor

Common; anaphylaxis has been reported rarely.
Off-label anti-aging marketing Moderate evidence

Widely promoted in wellness clinics for indications it has never been tested in.

Who should avoid it

Pregnancy
Active malignancy
Disrupted hypothalamic-pituitary axis from surgery, radiation or trauma
Uncontrolled diabetes (relative)

If used under medical supervision, monitor

Fasting glucose and HbA1c
IGF-1
Waist circumference or CT visceral fat
Age-appropriate cancer screening

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

Insulin and antidiabetic drugs — glucose intolerance is a recognised effect; requirements may increase
Corticosteroids — blunt the GH response
CYP3A4 substrates — GH can alter clearance; relevant with antiretroviral regimens in the labelled population
Simvastatin and ritonavir-boosted regimens — review interaction profiles in HIV patients

Regulatory & legal status

Prescription drug; on-label use is narrow. Compounded GHRH analogs sold for anti-aging are a different regulatory situation entirely.

Infographic

Tesamorelin — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

visceral fatgrowth hormoneHIV lipodystrophyliver fat

Related peptides in Growth Hormone Axis

Terms used on this page

Growth Hormone (GH): Growth hormone is a 191-amino-acid pituitary protein secreted in pulses that acts directly on tissues and indirectly through hepatic IGF-1, and is approved for a defined list of indications.
Visceral Adipose Tissue (VAT): Visceral adipose tissue is the intra-abdominal fat surrounding the organs, metabolically distinct from subcutaneous fat and more closely linked to cardiometabolic risk.
Negative Feedback Loop: A negative feedback loop is a control arrangement in which the output of a system inhibits its own production, holding the regulated variable near a set point and limiting how far any stimulus can push it.
Adiposity: Adiposity is the total quantity and anatomical distribution of body fat, treated as an active endocrine tissue rather than as inert storage.
Pulsatile vs Tonic Signalling: Pulsatile signalling delivers a hormone in discrete bursts whose frequency and amplitude carry the message, while tonic signalling exposes the receptor continuously, and the two can produce opposite effects.
Insulin-Like Growth Factor 1 (IGF-1): IGF-1 is a 70-amino-acid, proinsulin-like peptide produced mainly by the liver under growth hormone control, and it mediates most of the anabolic effects attributed to growth hormone.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.